Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors

Breast Cancer Clinical Trial

Official title:

Chemotherapy-Induced Cognitive Change and DNA Damage in Breast Cancer Survivors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00496613
• Other study ID #: 07-090
• Status: Completed
• Start date: June 2007
• Est. completion date: April 18, 2022

Study information

• Verified date: April 2022
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to learn more about how chemotherapy affects an individual's thinking abilities (cognition). Some research has shown that chemotherapy can cause changes in cognition in breast cancer survivors. However, it is not clear why this change occurs. In this study, the investigators will look to see if damage to DNA is related to these changes in cognition. Specifically, the investigators want to see 1) if women who have been treated with chemotherapy have more DNA damage than healthy women; and 2) if DNA damage is related to cognitive problems in breast cancer survivors and healthy women.

Description:

The primary objective of this proposal is to obtain preliminary data regarding the association between DNA damage and cognitive functioning in breast cancer survivors. Specifically, we predict that:

1. Breast cancer survivors treated with chemotherapy and hormonal therapy will have higher levels of DNA damage as measured by the Comet assay as compared to age and education matched survivors treated with hormonal therapy only and healthy controls.

2. Survivors who meet criteria for cognitive impairment will have higher levels of DNA damage as compared to cancer survivors who do not meet criteria for cognitive impairment and healthy controls.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: April 18, 2022
• Est. primary completion date: April 18, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 50 Years to 70 Years

Eligibility

Inclusion Criteria:

• Breast cancer survivors (Stage I-III) 2-6 years post all cancer treatments, but currently receiving hormone therapy.

• History of treatment with chemotherapy and/or hormonal therapy, or hormone therapy only.

• No evidence of active/recurrent disease.

• Less than 70 years old at time of recruitment.

• Post-menopausal prior to initial treatment.

• In the judgment of the consenting professional, is able to provide informed consent.

• Patient is able to understand English, through verbal and written communication.

Exclusion Criteria:

• Recurrence of breast cancer or diagnosis of another cancer except basal cell carcinoma.

• Exposure to chemotherapy or radiation therapy for any medical condition unrelated to breast cancer.

• Neurobehavioral risk factors including history of neurological disorder, or moderate to severe head trauma (loss of consciousness > 60 min or evidence of structural brain changes on imaging).

• Neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.

• Self-reported sleep disorders that could influence cognitive functioning including sleep apnea and chronic fatigue syndrome.

• Self-reported Axis I psychiatric disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia.

• Disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia.

• Male.

Healthy Control Inclusion Criteria:

• Have had no diagnosis of cancer except basal cell carcinoma.

• Less than 70 years old at time of recruitment.

• Post-menopausal.

• In the judgment of the consenting professional, is able to provide informed consent.

• Patient is able to understand English, through verbal and written communication

Healthy Control Exclusion Criteria:

• Exposure to chemotherapy or radiation therapy for any medical condition.

• Neurobehavioral risk factors including history of neurological disorder, or moderate to severe head trauma (loss of consciousness > 60 min or evidence of structural brain changes on imaging).

• Neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis etc.

• Self-reported sleep disorders that could influence cognitive functioning including sleep apnea and chronic fatigue syndrome.

• Self-reported Axis I psychiatric disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia.

• Male.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Long-Term Survivors

Intervention

Behavioral:
• Mini-Mental State Exam and Blood draw
The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
• Mini-Mental State Exam and Blood Draw
The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
• Mini-Mental State Exam and Blood Draw
The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center at Commack	Commack	New York
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Memorial Sloan Kettering Cancer Center at Mercy Medical Center	Rockville Centre	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary goal of this preliminary study is to examine the relationship between DNA damage and chemotherapy-induced cognitive changes in breast cancer survivors.		2 years

External Links

•   Memorial Sloan Kettering Cancer Center